Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Maria Eugenia Alvaro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Antineoplastic Agents, Immunological, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of bispecific antibodies that redirect T‐cell cytotoxicity toward malignant plasma cells. Elranatamab is a humanized BCMA × CD3 bispecific antibody that has demonstrated clinically meaningful activity in heavily pretreated RRMM. This review summarizes and critically appraises available evidence on elranatamab, focusing on its mechanism of action, clinical efficacy, safety profile, patient‐reported outcomes, and comparative positioning within the evolving BCMA‐directed treatment landscape. Across studies, elranatamab has shown high response rates, durable disease control, and manageable toxicity, with predominantly low‐grade cytokine release syndrome and limited neurotoxicity when administered with step‐up dosing. Emerging data indicate preserved efficacy in patients previously exposed to BCMA‐targeted therapies and feasibility in selected high‐risk populations, including those with severe renal impairment. Nevertheless, uncertainties remain regarding optimal sequencing, long‐term survival benefit, infection risk management, and mechanisms of resistance. Overall, elranatamab represents a valuable addition to the therapeutic armamentarium for RRMM. Ongoing studies and real‐world experience will be critical to refine its positioning, identify patients most likely to benefit, and define its role in combination strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
- Emergency and Internal Medicine Department, Saint Joseph Hospital, East Jerusalem, Palestine.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- AIL Sezione di Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Francesco Mendicino, Massimo Gentile
Zitieren
APA
Alvaro, M. E., Martino, E. A., Caserta, S., Skafi, M., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Vigna, E., Morabito, F., & Gentile, M. (2026). Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives. European Journal of Haematology. https://doi.org/10.1111/ejh.70167
Vancouver
Alvaro ME, Martino EA, Caserta S, Skafi M, Bruzzese A, Amodio N, et al. Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives. European Journal of Haematology. 2026. doi:10.1111/ejh.70167
BibTeX
@article{Alvaro2026,
author = {Alvaro, Maria Eugenia and Martino, Enrica Antonia and Caserta, Santino and Skafi, Mamdouh and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Vigna, Ernesto and Morabito, Fortunato and Gentile, Massimo},
title = {Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70167}
}
EUVIMED